|
|
by winston » Fri Nov 29, 2024 9:22 pm
Trading at a price-to-earnings (P/E) multiple of more than 80.
In the trailing 12 months, Eli Lilly has generated $40.9 billion in revenue and $8.4 billion in profit.
by winston » Thu Dec 05, 2024 9:29 am
Eli Lilly shares moved higher in early Wednesday trading following data from a study that showed its blockbuster weight loss treatment Zepbound to be more effective than market leader Wegovy.
Eli Lilly (LLY) said patients in a long-term study lost around 20.2% of their body weight while using Zepbound, compared with around 13.7% for those using the Novo Nordisk product, Novo Wegovy.
The study also noted that adult patients taking Zepbound who were either obese or overweight, but did not suffer from diabetes, achieved five key benchmarks that were superior to those taking Wegovy.
"Zepbound is in a class of its own as the only FDA-approved dual GIP and GLP-1 receptor agonist obesity medication, and it's changing how millions of people manage this chronic disease."
by winston » Thu Dec 05, 2024 12:10 pm
The company's trailing price-to-earnings (P/E) ratio tops 86 -- the average for the healthcare industry is less than a quarter of that at 18.
In a phase 3 study, Zepbound was associated with an average weight loss of up to 22.5% in patients after 72 weeks, compared to 4.3% for those taking a placebo.
Eli Lilly still has plenty of weight loss candidates in the pipeline, including one it is calling Triple G since it mimics the action of three different hormones: GLP-1, GIP, and glucagon.
Zepbound mimics the action of the first two, and it's clear how effective it is.
Kisunla, a recently approved Alzheimer's disease therapy; and muvalaplin, an investigational phase 2 medicine that just posted positive results in lowering lipoprotein (a), or LP(a), levels in adults at high risk of cardiovascular events.
Eli Lilly will earn plenty of approvals and label expansions in the next five years. The company's revenue and earnings should continue growing rapidly, especially as newer products like Kisunla start contributing.
by winston » Fri Dec 06, 2024 2:45 pm
Bearishly, Lilly missed third-quarter sales calls for Zepbound and Mounjaro, the diabetes treatment that uses the same chemical backbone.
Lilly is also facing off with compounders, who continue to make knockoff versions of tirzepatide, the key ingredient behind Zepbound and Mounjaro. The Food and Drug Administration is now looking at whether tirzepatide is actually in shortage.
Sales of Lilly's flagship product, tirzepatide, missed expectations. Mounjaro brought in $3.11 billion in sales. Sales rocketed 121%, but were short of forecasts for $3.77 billion. Zepbound, the weight-loss drug, generated $1.26 billion in sales, missing the Street's call for $1.73 billion.
by winston » Tue Dec 10, 2024 12:12 pm
by winston » Thu Dec 12, 2024 8:16 am
by winston » Fri Dec 13, 2024 5:37 pm
By April 2025, Eli Lilly expects it will have data to report on a late-stage trial for orforglipron, an oral GLP-1 medication that has been promising thus far.
In phase 2 trial results, the once-daily pill helped obese and overweight adults lose up to 14.7% of their body weight over a 36-week period.
Now, the phase 3 trial data is upcoming and if it proves to be just as promising and with no serious side effects.
by winston » Thu Jan 09, 2025 8:43 am
by winston » Tue Jan 14, 2025 10:47 pm
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
Expects $3.5 billion in Mounjaro sales in the fourth quarter, and $1.9 billion for Zepbound. Analysts had expected the drugs to bring in $5.35 billion and $2.08 billion, respectively,
Lilly said it expects 2025 sales between $58 billion and $61 billion. Analysts were expecting revenue of $58.52 billion.
by winston » Mon Jan 20, 2025 2:07 pm
On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at about $45 billion. That's about 32% more than it reported during the previous year, but less than he told us to expect a few short months ago.
On Oct. 30, Lilly told investors to expect 2024 revenue to land in a range between $45.4 billion and $46 billion.
Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing growth for a drug that launched in 2022.
Users browsing this forum: No registered users and 1 guest